SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ALIMERA SCIENCES
(NQNM:ALIM Last Sale: 5.72 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ALIM : $5.72)
$28,405 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
6120 Windward Parkway Research Report Earnings Snapshot - Last 11/06/18
Alpharetta, GA 30005 Fact Sheet
Phone: 678-990-5740 Financial Statements
Peer Comparison
Annual Reports

C. Daniel Myers, Co-Founder, CEO/Pres., David Holland, Co-Founder, Richard S. Eiswirth Jr., CFO
Focus on Iluvien, intended as the first ophthalmic drug therapy approved by the FDA for the treatment of DME. IPO at $11 April 21, 2010. Raised $72.1 million, selling 6.6 million shares, 21% of the outstanding. Lead Manager: CS First Boston.
Historical Charts    Technical Analysis
No Historical Data available for ALIM

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ALIM $5.72 $5.72 0 .0 $5.39 $5.93 5,004 $5.39 $5.93 4,965,949
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $28,405,228

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex